PRODUCT LITERATURE

Treatment of Chronic Low Back Pain With Etoricoxib, a New Cyclo-oxygenase-2 Selective Inhibitor: Improvement in Pain and Disability—A Randomized, Placebo-Controlled, 3-Month Trial

---

We evaluated etoricoxib, a novel COX-2–specific inhibitor, in 319 patients with chronic low back pain (LBP) in this double-blind, placebo-controlled trial. Patients were randomized to a 60 mg dose (n
103) or 90 mg dose (n
107) of etoricoxib, or placebo (n
109), daily for 12 weeks. The primary endpoint was low back pain intensity scale (Visual Analog Scale of 0- to 100-mm) timeweighted average change from baseline over 4 weeks. Other endpoints included evaluation over 3 months of low back pain intensity scale, Roland-Morris Disability Questionnaire (RMDQ), low back pain bothersomeness scale, patient- and investigator-global assessments, Patient Health Survey (MOS SF-12), rescue acetaminophen use, and discontinuation due to lack of efficacy

---

Availability

Detail Information

Series Title

-

Call Number

-

Publisher

: .,

Collation

-

Language

English

ISBN/ISSN

-

Classification

NONE

Content Type

-

Media Type

-

Carrier Type

-

Edition

-

Subject(s)

Orinox

Specific Detail Info

The Journal of Pain, Vol 4, No 6 (August), 2003: pp 307-315

Statement of Responsibility

-

Other version/related

File Attachment

Comments

---

You must be logged in to post a comment